<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35372712</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">2451-9936</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>26</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>American journal of ophthalmology case reports</Title>
          <ISOAbbreviation>Am J Ophthalmol Case Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Bilateral anterior and posterior scleritis in a patient with acute myelogenous leukemia.</ArticleTitle>
        <Pagination>
          <StartPage>101497</StartPage>
          <MedlinePgn>101497</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">101497</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajoc.2022.101497</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">To report a novel case of bilateral anterior and posterior scleritis in a patient with acute myelogenous leukemia (AML).</AbstractText>
          <AbstractText Label="OBSERVATIONS" NlmCategory="UNASSIGNED">A 69-year-old African American man was admitted to the hospital for relapse of AML. After admission, but prior to induction of chemotherapy, the patient developed ocular redness and proptosis. The diagnosis of bilateral anterior and posterior scleritis was made following an ophthalmic examination, infectious and autoimmune lab work-up, and neuroimaging. The patient was administered immunosuppressive therapy, clinically monitored, and initiated on chemotherapy for AML relapse. About one week later, the patient showed clinical improvement and resolution of the scleritis and proptosis.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Scleritis may present during AML relapse, and it may be due to a paraneoplastic syndrome or a reactive anti-leukemic inflammatory response. Clinicians should monitor patients with AML relapse for symptoms such as ocular redness, proptosis, pain, photophobia, and decreased vision, which may indicate development of scleritis.</AbstractText>
          <CopyrightInformation>© 2022 The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Patel</LastName>
            <ForeName>Pujan R</ForeName>
            <Initials>PR</Initials>
            <AffiliationInfo>
              <Affiliation>Drexel University College of Medicine, Philadelphia, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Farrell</LastName>
            <ForeName>Maureen C</ForeName>
            <Initials>MC</Initials>
            <AffiliationInfo>
              <Affiliation>Drexel University College of Medicine, Philadelphia, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peshtani</LastName>
            <ForeName>Ani</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Drexel University College of Medicine, Philadelphia, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Berkenstock</LastName>
            <ForeName>Meghan K</ForeName>
            <Initials>MK</Initials>
            <AffiliationInfo>
              <Affiliation>Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Am J Ophthalmol Case Rep</MedlineTA>
        <NlmUniqueID>101679941</NlmUniqueID>
        <ISSNLinking>2451-9936</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Acute myelogenous leukemia</Keyword>
        <Keyword MajorTopicYN="N">Anterior scleritis</Keyword>
        <Keyword MajorTopicYN="N">Anti-leukemic inflammatory response</Keyword>
        <Keyword MajorTopicYN="N">Paraneoplastic syndrome</Keyword>
        <Keyword MajorTopicYN="N">Posterior scleritis</Keyword>
      </KeywordList>
      <CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>4</Day>
          <Hour>5</Hour>
          <Minute>34</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35372712</ArticleId>
        <ArticleId IdType="pmc">PMC8971595</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ajoc.2022.101497</ArticleId>
        <ArticleId IdType="pii">S2451-9936(22)00243-2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Calthorpe C.M., Watson P.G., McCartney A.C. Posterior scleritis: a clinical and histological survey. Eye. 1988;2(Pt 3):267–277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3402623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okhravi N., Odufuwa B., McCluskey P., Lightman S. Scleritis. Surv Ophthalmol. 2005;50(4):351–363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15967190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCluskey P.J., Watson P.G., Lightman S., et al.  Posterior scleritis: clinical features, systemic associations, and outcome in a large series of patients. Ophthalmol. 1999;106(12):2380–2386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10599675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daniel Diaz J., Sobol E.K., Gritz D.C. Treatment and management of scleral disorders. Surv Ophthalmol. 2016;61(6):702–717.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27318032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzalez-Gonzalez L.A., Molina-Prat N., Doctor P., et al.  Clinical features and presentation of posterior scleritis: a report of 31 cases. Ocul Immunol Inflamm. 2014;22(3):203–207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24131324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loriaut P., Charlotte F., Bodaghi B., et al.  Choroidal and adnexal extranodal marginal zone B-cell lymphoma: presentation, imaging findings, and therapeutic management in a series of nine cases. Eye. 2013;27(7):828–835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3709394</ArticleId>
            <ArticleId IdType="pubmed">23598677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaucher D., Bodaghi B., Charlotte F., et al.  [MALT-type B-cell lymphoma masquerading as scleritis or posterior uveitis] J Fr Ophtalmol. 2005;28(1):31–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15767896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalogeropoulos D., Katsikatsos K., Mitsis M., Kalogeropoulos C. Posterior scleritis as a paraneoplastic syndrome in colon cancer: a case report. Turk J Ophthalmol. 2020;50(6):377–380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7802099</ArticleId>
            <ArticleId IdType="pubmed">33389939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thakker M.M., Perez V.L., Moulin A., Cremers S.L., Foster C.S. Multifocal nodular episcleritis and scleritis with undiagnosed Hodgkin's lymphoma. Ophthalmol. 2003;110(5):1057–1060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12750114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hunyor A.P., Harper C.A., O'Day J., McKelvie P.A. Ocular-central nervous system lymphoma mimicking posterior scleritis with exudative retinal detachment. Ophthalmol. 2000;107(10):1955–1959.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11013206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dorey S.E., Clark B.J., Christopoulos V.A., Lightman S. Orbital lymphoma misdiagnosed as scleritis. Ophthalmol. 2002;109(12):2347–2350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12466182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoang-Xuan T., Bodaghi B., Toublanc M., et al.  Scleritis and mucosal-associated lymphoid tissue lymphoma: a new masquerade syndrome. Ophthalmol. 1996;103(4):631–635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8618763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kirn T.J., Levy N.B., Gosselin J.J., Rosen W.J., Zegans M.E. Peripheral T-cell lymphoma presenting as sclerouveitis. Cornea. 2007;26(9):1147–1149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17893556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeo J.H., Jakobiec F.A., Iwamoto T., Brown R., Harrison W. Metastatic carcinoma masquerading as scleritis. Ophthalmol. 1983;90(2):184–194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6304588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohsenin A., Sinard J., Huang J.J. Necrobiotic xanthogranuloma and chronic lymphocytic leukemia of the conjunctiva masquerading as scleritis and uveitis. Clin Ophthalmol. 2012;6:2045–2047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3526909</ArticleId>
            <ArticleId IdType="pubmed">23271884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Green W., Rao P.K., Harocopos G.J. Extramedullary relapse of acute myelogenous leukemia presenting as a large serous retinal detachment. Ocul Oncol Pathol. 2017;3(2):95–100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5566763</ArticleId>
            <ArticleId IdType="pubmed">28868277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anguille S., Van Tendeloo V.F., Berneman Z.N. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia. 2012;26(10):2186–2196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22652755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anguille S., Lion E., Smits E., Berneman Z.N., van Tendeloo V.F. Dendritic cell vaccine therapy for acute myeloid leukemia: questions and answers. Hum Vaccine. 2011;7(5):579–584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21422813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scholl S., Salzmann S., Kaufmann A.M., Hoffken K. Flt3-ITD mutations can generate leukaemia specific neoepitopes: potential role for immunotherapeutic approaches. Leuk Lymphoma. 2006;47(2):307–312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16321862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soon A.K., Chan T.Y. An atypical case of bilateral posterior scleritis in a patient with chronic lymphocytic leukemia. Can J Ophthalmol. 2015;50(4):e60–e63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26257236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vergouwen D.P.C., Rothova A., Berge J.C.T., et al.  Current insights in the pathogenesis of scleritis. Exp Eye Res. 2020;197:108078.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32504648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bernauer W., Buchi E.R., Daicker B. Immunopathological findings in posterior scleritis. Int Ophthalmol. 1994;18(4):229–231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7797388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palexas G.N., Puren A., Savage N., Welsh N.H. Serum interleukin (IL-1 beta) in patients with diffuse scleritis. Scand J Immunol Suppl. 1992;11:171–172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1514036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seo K.Y., Lee H.K., Kim E.K., Lee J.H. Expression of tumor necrosis factor alpha and matrix metalloproteinase-9 in surgically induced necrotizing scleritis. Ophthalmic Res. 2006;38(2):66–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16319517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larson T.A., Hu M., Janik J.E., et al.  Interleukin-2 receptor targeted therapy of ocular disease of HTLV-1-associated adult T-cell leukemia. Ocul Immunol Inflamm. 2012;20(4):312–314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22642512</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
